Merck Japan says it will accelerate imports of COVID-19 treatment
Merck Japan says it will accelerate imports of COVID-19 treatment

Merck Japan says it will accelerate imports of COVID-19 treatment

Signage seen at Merck & Co.’s headquarters in Kenilworth, New Jersey, USA, November 13, 2021. REUTERS / Andrew Kelly

Sign up now for FREE unlimited access to Reuters.com

TOKYO, February 14 (Reuters) – The Japanese entity in Merck & Co Inc (MRK.N) said Monday that it would accelerate imports of its oral COVID-19 treatment to help with an increase in cases caused by the Omicron variant.

The company will deliver 800,000 cures of the antiviral molnupiravir to Japan in March, up from the previously planned 600,000, a statement said.

Japan agreed last year to pay Merck and its partner Ridgeback Biotherapeutics about $ 1.2 billion for 1.6 million courses of molnupiravir. The drug was approved by regulators in late December.

Sign up now for FREE unlimited access to Reuters.com

Reporting by Rocky Swift; Editing Kim Coghill

Our standards: Thomson Reuters trust principles.

Leave a Reply

Your email address will not be published.